Affimed N.V.

Affimed N.V.verified

AFMD

Price:

$3.95

Market Cap:

$54.09M

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid ...[Read more]

Industry

Biotechnology

IPO Date

2014-09-12

Stock Exchange

NASDAQ

Ticker

AFMD

The Enterprise Value as of September 2024 (TTM) for Affimed N.V. (AFMD) is 57.84M

According to Affimed N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 57.84M. This represents a change of -12.05% compared to the average of 65.76M of the last 4 quarters.

Affimed N.V. (AFMD) Historical Enterprise Value (quarterly & annually)

How has AFMD Enterprise Value performed in the past?

The mean historical Enterprise Value of Affimed N.V. over the last ten years is 110.49M. The current 57.84M Enterprise Value has changed 5.13% with respect to the historical average. Over the past ten years (40 quarters), AFMD's Enterprise Value was at its highest in in the June 2021 quarter at 645.78M. The Enterprise Value was at its lowest in in the March 2023 quarter at -27718859.82.

Quarterly (TTM)
Annual

Average

110.49M

Median

69.68M

Minimum

-7236343.14

Maximum

401.16M

Affimed N.V. (AFMD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Affimed N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 324.68%

Maximum Annual Enterprise Value = 401.16M

Minimum Annual Increase = -1002.36%

Minimum Annual Enterprise Value = -7236343.14

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202365.30M-1002.36%
2022-7236343.14-101.80%
2021401.16M59.24%
2020251.93M288.10%
201964.91M-12.34%
201874.05M324.68%
201717.44M-32.81%
201625.95M-77.34%
2015114.54M18.25%
201496.86M-3.18%

Affimed N.V. (AFMD) Average Enterprise Value

How has AFMD Enterprise Value performed in the past?

The current Enterprise Value of Affimed N.V. (AFMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

153.07M

5-year avg

155.21M

10-year avg

110.49M

Affimed N.V. (AFMD) Enterprise Value vs. Peers

How is AFMD’s Enterprise Value compared to its peers?

Affimed N.V.’s Enterprise Value is greater than TCR2 Therapeutics Inc. (49.64M), greater than Pieris Pharmaceuticals, Inc. (2.03M), less than ADC Therapeutics SA (125.33M), less than Agenus Inc. (449.78M), greater than X4 Pharmaceuticals, Inc. (51.42M), less than Terns Pharmaceuticals, Inc. (567.79M), less than Day One Biopharmaceuticals, Inc. (966.49M), less than PDS Biotechnology Corporation (78.49M), less than Inozyme Pharma, Inc. (406.63M), greater than Leap Therapeutics, Inc. (38.33M), less than Adaptimmune Therapeutics plc (119.37M), less than Corvus Pharmaceuticals, Inc. (366.80M), greater than Aptose Biosciences Inc. (-846639.00), greater than eFFECTOR Therapeutics, Inc. (3.86M), greater than Elevation Oncology, Inc. (8.23M), less than Mereo BioPharma Group plc (597.60M), greater than Hepion Pharmaceuticals, Inc. (2.10M),

Build a custom stock screener for Affimed N.V. (AFMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Affimed N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Affimed N.V. (AFMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Affimed N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Affimed N.V.'s Enterprise Value?

What is the highest Enterprise Value for Affimed N.V. (AFMD)?

What is the 3-year average Enterprise Value for Affimed N.V. (AFMD)?

What is the 5-year average Enterprise Value for Affimed N.V. (AFMD)?

How does the current Enterprise Value for Affimed N.V. (AFMD) compare to its historical average?